Stem cell-derived immune cells in pediatric cancer therapy: From bench to bedside

Abstract

Immune effector cells generated from stem cell sources, most notably induced pluripotent stem cells and hematopoietic stem cells (HSCs) differentiated into natural killer cells, T lymphocytes, and dendritic cells, represent a rapidly advancing category of off-the-shelf immunotherapies for pediatric cancers. In contrast to autologous chimeric antigen receptor-T-cell products, stem cell-based platforms enable the use of standardized, clonally controlled starting materials, support complex and multiplex genetic modifications, and facilitate scalable manufacturing processes that may substantially reduce production time and batch-to-batch heterogeneity. However, HSC-derived immune cells may preserve aspects of physiological immune maturation that enhance persistence and functional durability in vivo. Accumulating preclinical and early-phase clinical evidence has demonstrated potent antitumor activity against pediatric hematologic malignancies and select solid tumors, alongside encouraging safety profiles characterized by minimal graft-vs-host disease and reduced severe neurotoxicity, as well as compatibility with cryopreserved delivery. Nonetheless, key translational challenges remain unresolved, including the absence of robust head-to-head comparisons between induced pluripotent stem cell-derived and HSC-derived products; limited cost-effectiveness analyses relative to established therapies; and unresolved manufacturing constraints related to genomic stability, differentiation reproducibility, and potency assessment. Systematic comparative studies, transparent health-economic modeling, and rational engineering strategies emphasizing genomic monitoring, immune evasion control, and programmable safety mechanisms will be critical for defining the most appropriate clinical applications of stem cell-derived immunotherapies in pediatric oncology.

Key Words: Stem cell-derived immunotherapy; Pediatric oncology; Induced pluripotent stem cells; Chimeric antigen receptor-based cell therapy; Natural killer cells; Allogeneic immune effectors

Core Tip: Immune cells generated from pluripotent or hematopoietic stem cell sources -particularly natural killer cells, T lymphocytes, and dendritic cells - represent a promising next-generation platform for pediatric cancer immunotherapy. These systems enable standardized, renewable production and genetic optimization, offering an allogeneic alternative to patient-specific cellular products with lower graft-vs-host disease risk. Advances in cytokine modulation and genome editing technologies, including CRISPR/Cas9, have further strengthened antitumor efficacy. This review critically consolidates current preclinical and early-phase clinical findings; addresses manufacturing, safety, and pediatric ethical considerations; and defines strategic directions for clinical translation.

INTRODUCTION

Pediatric malignancies affect an estimated 400000 children each year worldwide, constituting a profound global health burden that necessitates the development of innovative therapeutic strategies[1]. Although major advances have been achieved through conventional treatment modalities - such as chemotherapy, radiotherapy, and hematopoietic stem cell (HSC) transplantation - significant unmet clinical needs remain[2,3]. In high-income settings, current protocols have increased overall survival rates to nearly 80%; however, a considerable proportion of pediatric patients still experience disease recurrence, develop resistance to therapy, or endure severe long-term treatment-related toxicities that may compromise health and quality of life well into adulthood[4].

Adoptive cellular immunotherapy has emerged as a transformative approach in pediatric oncology, particularly with the introduction of chimeric antigen receptor (CAR) T-cell therapies. Clinical studies have reported exceptional therapeutic responses to CD19-directed CAR-T cells in children with relapsed or refractory B-acute lymphoblastic leukemia (ALL), with complete remission rates exceeding 90% in select cohorts[5]. Despite these remarkable outcomes, several fundamental challenges limit the broader integration of CAR-T-cell therapy across pediatric cancer indications.

A major impediment lies in the manufacturing process itself. Current CAR-T-cell products are predominantly autologous and require individualized leukapheresis, ex vivo genetic modification, and cellular expansion. This labor-intensive process often lasts several weeks and may be unsuccessful in up to 30% of heavily pretreated pediatric patients due to inadequate T-cell quantity or functional impairment[6]. Moreover, the sophisticated production infrastructure and high financial burden - frequently surpassing $400000 per patient - severely restrict global accessibility. Safety concerns further constrain clinical implementation, as treatment-associated toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occur in up to 40% of pediatric recipients and may necessitate intensive care interventions[7,8]. In addition to acute toxicity, the prolonged persistence of genetically engineered T cells raises unresolved concerns regarding long-term immune surveillance and potential delayed adverse effects in children with developing immune systems. Collectively, these limitations have driven growing interest in alternative cellular immunotherapy platforms capable of overcoming the inherent constraints of autologous CAR-T-cell approaches. Among these, stem cell-derived immune cells have gained significant attention because of their potential to provide renewable cell sources, standardized and scalable manufacturing, shortened production timelines, and improved safety profiles[9,10].

Induced pluripotent stem cells (iPSCs) represent a particularly attractive platform for immune cell generation. Since their initial development in 2006, iPSCs have demonstrated extensive utility in regenerative medicine owing to their indefinite self-renewal capacity and pluripotency, enabling their differentiation into a wide range of functional immune effector populations[11,12]. The clonal derivation of iPSC lines facilitates precise and reproducible genetic engineering via technologies such as CRISPR/Cas9, allowing targeted enhancements of antitumor efficacy while simultaneously reducing the risk of treatment-related toxicity.

HSCs constitute an additional and complementary source for immune cell production, offering a differentiation trajectory that closely mirrors physiological hematopoiesis. Immune cells derived from HSCs may therefore retain more native functional properties, potentially leading to improved persistence and biological performance following in vivo administration[13].

Both iPSC-based and HSC-based platforms have enabled the development of allogeneic, “off-the-shelf” cellular immunotherapies that can be manufactured in advance, rigorously quality controlled, cryopreserved, and rapidly administered as clinically needed[14,15]. Such strategies have the potential to reduce treatment initiation times from weeks to days, enhance batch-to-batch consistency, and substantially lower costs through scalable production models[16,17]. The convergence of stem cell biology with advanced genome engineering technologies has thus created unprecedented opportunities for the design of next-generation cellular immunotherapies tailored specifically to pediatric oncology. This review provides a comprehensive overview of the current landscape of stem cell-derived immune cell therapies, emphasizing their capacity to address the unique biological, clinical, and logistical challenges inherent to the treatment of childhood cancers while mitigating the limitations associated with existing immunotherapeutic modalities.

LITERATURE REVIEW

A targeted literature search was conducted across PubMed/MEDLINE, EMBASE, Scopus, Web of Science, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform for studies indexed up to December 31, 2025. Search strategies combined terms related to stem cell sources (e.g., “induced pluripotent stem cell” OR iPSC OR “hematopoietic stem cell” OR HSC), immune effector cell types (“natural killer” OR NK OR “T-cell” OR “dendritic cell” OR CAR), and the pediatric context (pediatric OR pediatric OR child OR adolescent OR “childhood cancer”). Additional queries were applied to capture studies involving genetic engineering and manufacturing approaches, including CRISPR, interleukin-15 (IL-15), good manufacturing practice (GMP), and bioreactor technologies, where applicable. The records included original preclinical investigations; interventional clinical trials; observational clinical reports; and systematic reviews addressing the development, engineering, production, or clinical translation of stem cell-derived immune effectors in pediatric cancers. Nonempirical commentaries and studies published in languages other than English were excluded.

STEM CELL SOURCES FOR IMMUNE-CELL DERIVATION

The choice of stem cell origin constitutes a pivotal determinant in the development of cellular immunotherapies, as each platform confers distinct advantages and constraints that influence manufacturability, product uniformity, and clinical translation. Modern strategies for immune cell production have expanded beyond the traditional dependence on peripheral blood and umbilical cord blood, incorporating advanced stem cell-based systems that afford greater control over cellular attributes and enable scalable manufacturing pipelines[18].

Among the available platforms, iPSCs have emerged as the most adaptable source for immune cell generation, addressing several inherent limitations associated with conventional donor-derived approaches. iPSCs can be generated from readily obtainable somatic tissues, including dermal fibroblasts and peripheral blood mononuclear cells, through reprogramming with defined transcription factors, resulting in a self-renewing cell population with virtually unlimited expansion capacity[19]. This feature circumvents donor availability constraints and supports the creation of master cell banks capable of sustaining large-scale, reproducible production.

The clonal derivation of iPSC lines enables an unparalleled level of genetic precision and quality oversight. In contrast to heterogeneous primary immune cell populations, iPSCs can undergo comprehensive genomic and epigenomic characterization prior to differentiation, facilitating the selection of clones with optimal biological and safety profiles[20]. This strategy allows for the deliberate incorporation of multiple genetic alterations via state-of-the-art genome editing technologies, yielding engineered immune cells with enhanced therapeutic functionality that would be challenging to achieve via primary cell sources.

Advances in iPSC maintenance and differentiation methodologies have substantially mitigated earlier concerns regarding the clinical suitability of pluripotent stem cell-derived products. The adoption of feeder-free culture conditions and fully defined media formulations has eliminated reliance on xenogeneic components, while refined differentiation protocols now enable the generation of immune effector cells that closely mirror their primary counterparts with respect to phenotype, functional capacity, and transcriptional signatures[21]. Notably, iPSC-derived natural killer (NK) cells have demonstrated antitumor cytotoxicity that is comparable to, or in some contexts surpasses, that of peripheral blood-derived NK cells, including in pediatric tumor models.

HSCs provide an alternative and biologically intuitive route for immune cell production, leveraging endogenous developmental programs that give rise to all hematopoietic lineages. HSCs may be obtained from bone marrow, mobilized peripheral blood, or umbilical cord blood, with each source offering distinct advantages related to cell yield, proliferative potential, and differentiation efficiency[22]. Immune cells generated from HSCs may therefore retain features more closely aligned with physiological immune development, potentially enhancing functional performance and in vivo persistence.

Umbilical cord blood has attracted particular interest as a source of HSCs owing to its widespread availability, lower risk of transmissible infections, and increased proliferative capacity. Compared with adult peripheral blood NK cells, cord blood-derived NK cells display favorable immunobiological properties, including increased tumor-directed cytotoxicity and reduced expression of inhibitory receptors[23]. In addition, the extensive global infrastructure of cord blood banking facilitates access to diverse human leukocyte antigen (HLA) profiles, supporting the feasibility of off-the-shelf allogeneic cellular products.

Comparative evaluation of stem cell-derived vs conventional primary immune cell sources highlights several advantages that favor the adoption of stem cell platforms for clinical use. Primary NK cells isolated from peripheral or cord blood exhibit marked inter-donor variability in terms of cell yield, expansion capacity, and functional potency, complicating efforts to standardize manufacturing and ensure product consistency. In contrast, stem cell-based strategies enable the generation of homogeneous cell populations with predictable and reproducible properties, thereby facilitating standardized production workflows compatible with regulatory requirements[24,25].

Scalability represents an additional and critical strength of stem cell-based manufacturing. Whereas primary immune cell production is constrained by the finite number of cells obtained from individual donors, stem cell platforms can theoretically generate limitless quantities of therapeutic cells from a single well-characterized master cell bank. This capability is particularly relevant for pediatric indications, where smaller patient cohorts and lower dosing demands may limit the economic feasibility of donor-dependent manufacturing systems[26].

The amenability of stem cells to genetic manipulation further enhances their therapeutic potential. Unlike primary immune cells, which are often resistant to extensive genetic modifications owing to their limited proliferative capacity and sensitivity to ex vivo manipulation, stem cells readily accommodate complex engineering strategies, including multiplex gene editing, transgene integration, and programmable regulatory elements[27]. These capabilities have facilitated the development of next-generation cellular immunotherapies featuring improved persistence, enhanced tumor targeting, and integrated safety controls.

Finally, the use of clonal stem cell sources substantially strengthens quality assurance and product characterization frameworks. The uniformity of stem cell-derived populations allows rigorous evaluation at multiple stages of production, from master cell bank establishment to final product release. This level of control offers a greater degree of confidence in product safety, consistency, and efficacy than heterogeneous primary cell preparations, which may harbor poorly defined or variable subpopulations[28]. Figure 1 provides an overview of the principal stem cell sources and their subsequent processing into functional immune effector cells, emphasizing the streamlined workflow and the translational benefits associated with off-the-shelf cellular immunotherapy platforms.

Figure 1 Overview of stem cell sources and a streamlined workflow for manufacturing immune effector cells. A: Summarizing the main cellular inputs, including induced pluripotent stem cells, hematopoietic stem cells, umbilical cord blood, and adult peripheral blood, highlighting their unique biological features and translational benefits that impact production scalability, product uniformity, and clinical feasibility; B: Illustrating the stepwise manufacturing process, beginning with cell procurement or somatic cell reprogramming, followed by expansion and master cell bank generation, lineage-specific immune differentiation, genetic engineering and functional maturation, good manufacturing practice-compliant quality control, cryopreservation, and final product formulation. Collectively, the figure emphasizes the translational advantages of stem cell-based platforms, including large-scale manufacturability, minimized donor-to-donor variation, reproducible therapeutic products and advanced genetic engineering capabilities that increase immune cell efficacy, durability and safety. iPSCs: Induced pluripotent stem cells; HSCs: Hematopoietic stem cells.

DIFFERENTIATION PROTOCOLS AND MOLECULAR ENGINEERING

The successful development of stem cell-derived immune cell therapies relies fundamentally on robust differentiation strategies capable of producing functional immune effector cells while supporting scalable manufacturing. Over the past decade, methodologies for deriving immune cells from stem cells have advanced considerably, integrating insights from developmental biology, bioprocess engineering, and genetic engineering to generate increasingly sophisticated and clinically relevant cell products[29].

Among these, the differentiation of NK cells from iPSCs has emerged as one of the most advanced applications. Early methods required stromal cell cocultures and extended differentiation periods of several months, limiting their clinical feasibility. Modern protocols have streamlined these processes using feeder-free systems with defined cytokine combinations and small molecules to guide NK cell specification[30]. Current staged approaches can generate functional NK cells within 4-6 weeks, first inducing hematopoietic specification and subsequently promoting NK lineage commitment and maturation.

NK cell differentiation from iPSCs is orchestrated by sequential activation of transcriptional networks governing hematopoietic development. Initial induction involves mesoderm and hematopoietic specification through bone morphogenetic protein 4, vascular endothelial growth factor, and stem cell factor. Subsequent cytokine exposure - Fms-like tyrosine kinase 3 ligand, IL-7, and IL-15 - drives NK progenitor emergence, followed by maturation supported by IL-2 and IL-21[31]. The optimized protocols achieve differentiation efficiencies exceeding 60%, producing NK cells expressing hallmark markers, including CD56, NKG2D, and diverse killer immunoglobulin-like receptors.

T-cell generation from pluripotent stem cells remains technically challenging because of the need for thymic microenvironments and T-cell receptor rearrangement. Recent advances have employed thymic organoid-based three-dimensional cultures that recapitulate key structural and functional aspects of the thymus, supporting functional T-cell development with proper T-cell receptor rearrangement and selection[32]. Alternative strategies use defined factor cocktails to bypass organoid dependency, facilitating the scalable production of clinically relevant T cells.

Dendritic cell (DC) differentiation has similarly benefited from detailed knowledge of myeloid lineage pathways. Current methods efficiently generate conventional DCs, plasmacytoid DCs, and Langerhans cells from iPSCs or hematopoietic progenitors via the use of lineage-specific cytokines[33]. iPSC-derived DCs exhibit robust antigen presentation and T-cell activation capabilities, underscoring their potential as cellular vaccines in cancer immunotherapy.

The advent of CRISPR/Cas9 technology has revolutionized genetic engineering in stem cell-derived immune cells, allowing precise modifications that enhance therapeutic function without compromising safety[34]. The high transfection efficiency and genomic stability of stem cells make them ideal for gene editing, enabling applications such as knockout of inhibitory receptors, insertion of synthetic CARs, and metabolic pathway modifications to improve persistence and functionality.

Cytokine signaling modulation is another critical approach for optimizing stem cell-derived immune cells. IL-15 is pivotal for NK cell survival, proliferation, and cytotoxicity; engineering strategies include introducing genes encoding IL-15 or its receptor to create autocrine support, which enhances NK cell persistence and antitumor activity in preclinical models[35]. Complementary IL-21 modifications improve NK cell maturation, metabolic fitness, and expansion capacity[36]. Combined IL-15/IL-21 engineering synergistically enhances therapeutic potential.

Targeting negative regulators such as cytokine-inducible SH2-containing protein (CISH) further augments cytokine responsiveness. CISH deletion in iPSC-derived NK cells enhances Janus kinase-signal transducer and activator of transcription signaling, leading to superior proliferation, metabolic fitness, and cytotoxicity in vitro and in vivo[37]. Integrating CISH knockout with additional genetic modifications result in highly potent NK cells with improved antitumor efficacy. Enhancing antibody-dependent cellular cytotoxicity (ADCC) through CD16 engineering addresses limitations caused by proteolytic cleavage of endogenous receptors. Strategies include noncleavable CD16 variants and high-affinity allotypes that maintain surface expression and antibody binding, significantly increasing ADCC in combination with therapeutic monoclonal antibodies[38].

Finally, advanced multigene circuits and synthetic biology approaches offer precise control over engineered immune cells. Inducible caspase-9 systems provide safety switches for selective cell elimination, whereas conditional expression platforms enable temporal regulation of therapeutic gene activity, maximizing efficacy and minimizing toxicity[39]. These innovations are particularly critical in pediatric settings, where long-term safety remains paramount. Figure 2 provides an overview of contemporary differentiation paradigms and molecular engineering strategies for the generation of immune effector cells from pluripotent stem cells, emphasizing the stepwise development of NK cells, T lymphocytes, and DC subsets, alongside integrated genetic and cytokine-based modifications designed to improve cellular function, durability, and safety in translational immunotherapy.

Figure 2 Differentiation frameworks and molecular engineering approaches for stem cell-derived immune cell therapies. Induced pluripotent stem cells are first directed toward hematopoietic progenitors and subsequently differentiated into natural killer cells, T lymphocytes, or dendritic cells using lineage-specific cytokines and organoid- or three-dimensional culture systems, yielding immune populations with robust cytotoxic activity and effective antigen presentation. Targeted molecular modifications - including CRISPR/Cas9-mediated gene editing, cytokine signaling enhancement, CD16 engineering, and the incorporation of controllable safety switches -improve cellular persistence, functional potency, and therapeutic safety. This combined differentiation and engineering strategy supports the scalable generation of highly effective, precisely tailored immune effector cells for advanced immunotherapy applications. NK: Natural killer; iPSCs: Induced pluripotent stem cells; BMP4: Bone morphogenetic protein 4; VEGF: Vascular endothelial growth factor; FLT3 L: Fms-like tyrosine kinase 3 ligand; IL: Interleukin; SCF: Stem cell factor; DC: Dendritic cell; CAR: Chimeric antigen receptor; CISH: Cytokine-inducible SH2-containing protein; 3D: Three-dimensional.

PRECLINICAL EVIDENCE IN PEDIATRIC MALIGNANCIES

Preclinical investigations have highlighted the potent antitumor activity of stem cell-derived immune cells across major pediatric malignancies, providing compelling evidence for their translational potential and supporting progression toward clinical evaluation. These studies have employed sophisticated in vitro functional assays and in vivo xenograft models to assess the efficacy, safety, and mechanistic underpinnings of stem cell-based immunotherapies in childhood cancers[40].

ALL has been the most extensively explored pediatric malignancy in stem cell-derived immunotherapy research, reflecting both its prevalence and the established efficacy of CD19-targeted strategies. iPSC-derived NK cells engineered with CD19-specific CARs exhibit robust cytotoxicity against ALL cell lines and primary patient samples in vitro[41]. Notably, these CAR-NK cells can achieve cytotoxic effects comparable to or greater than those of conventional CAR-T cells while avoiding the risk of graft-vs-host disease associated with allogeneic T-cell therapies[42,43].

In pediatric ALL xenograft models, CD19-CAR iPSC-NK cells significantly reduced tumor size and improved survival. NSG mice engrafted with Nalm-6 or REH leukemia models showed marked tumor clearance without observable toxicity, which contrasts with the findings of some preclinical studies in which CAR-T cells were reported to have adverse effects[44]. The favorable safety profile of NK cell therapies is particularly advantageous in pediatric settings, where minimizing treatment-related toxicity is critical[45]. The incorporation of IL-15 into CD19-CAR iPSC-NK cells further enhances antitumor efficacy. IL-15-expressing CAR-NK cells exhibit prolonged persistence in xenograft models, maintaining detectable populations for several weeks post-infusion. This autocrine support promotes more durable antitumor responses and reduces relapse risk while minimizing the need for exogenous cytokine administration, simplifying clinical translation and lowering potential side effects[43,46].

Neuroblastoma, a type of pediatric solid tumor, is notably susceptible to NK cell-mediated cytotoxicity. Studies have shown that activated NK cells effectively target neuroblastoma cell lines such as SK-N-BE(2), IMR-32, and LAN-1, with IL-15 pre-activation further enhancing their cytotoxicity[47,48]. Stem cell-derived NK platforms recapitulate these effects, achieving comparable or superior antitumor activity. Neuroblastoma biology provides inherent advantages for NK cell therapy: Frequent downregulation of HLA class I renders tumors resistant to T-cell immunity but sensitive to NK “missing self” recognition, and stress-induced ligands such as MICA and MICB engage NKG2D receptors on NK cells, enabling multiple activation pathways[49,50]. Genetic engineering has increased the efficacy of NK cells against neuroblastoma, as iPSC-derived NK cells expressing GD2-specific CARs demonstrate exceptional cytotoxicity against neuroblastoma cell lines and patient-derived xenografts. GD2 is an ideal target because of its high tumor-specific expression and limited presence in normal tissues, enabling potent tumor clearance without on-target, off-tumor toxicity in orthotopic models[51].

Osteosarcoma represents another promising indication for NK cell therapy. Osteosarcoma cell lines are highly sensitive to NK-mediated killing, which is further enhanced by IL-15 activation[52]. Importantly, patient-derived NK cells maintain cytotoxic activity against autologous tumors, indicating that allogeneic NK approaches could be highly effective[53]. The immunosuppressive microenvironment and low mutational burden of osteosarcoma often limit T-cell infiltration and activity; however, NK cells can circumvent these barriers through HLA-independent recognition of stress-induced ligands[54]. IPSC-derived NK cells have achieved greater than 60% cytotoxicity in primary osteosarcoma samples, with engineered receptors or cytokine support further enhancing efficacy across multiple tumor subtypes[55]. Additional pediatric solid tumors, including Ewing sarcoma, rhabdomyosarcoma, and Wilms tumor, exhibit varying degrees of NK cell sensitivity. Analysis of NK receptor-ligand expression patterns across these malignancies can inform optimized targeting strategies for each tumor type[56].

Mechanistic studies revealed that stem cell-derived NK cells exert multifaceted antitumor effects. Unlike CAR-T cells, which rely primarily on synthetic receptor engagement, engineered NK cells retain a full complement of native receptors, allowing simultaneous recognition of tumor cells through multiple pathways. This receptor redundancy mitigates antigen escape and enhances activity against heterogeneous tumor populations[57]. In addition to direct cytotoxicity, stem cell-derived NK cells exert immunomodulatory effects that enhance endogenous antitumor immunity. They promote DC activation, augment T-cell priming, remodel the tumor microenvironment, and support durable immune responses, an effect particularly critical in solid tumors where long-term immunological surveillance is essential to prevent relapse[58]. As summarized in Table 1, stem cell-derived immune cell therapies exhibit consistent antitumor activity and favorable safety profiles, supporting their progression toward clinical application in pediatric oncology.

Table 1 Summary of preclinical studies investigating stem cell-derived immune cell-based therapies in pediatric patients with cancer.

Pediatric malignancy/classification	Stem cell-based platform and experimental models	Key preclinical outcomes	Mechanistic rationale and translational relevance	Ref.
Broad preclinical context	Advanced in vitro functional systems and pediatric xenograft models	Consistent antitumor efficacy with reproducible safety and mechanistic validation	Provides foundation for clinical translation	[39]
ALL	iPSC-derived CD19-CAR NK cells; NSG xenografts (Nalm-6, REH)	Potent cytotoxicity with tumor regression and survival benefit without toxicity	Comparable or superior to CAR-T with reduced GvHD risk	[53,55]
ALL - cytokine enhancement	IL-15-expressing CD19-CAR iPSC-NK; persistence xenografts	Enhanced persistence and durable tumor control without systemic cytokines	Autocrine IL-15 improves durability and clinical feasibility	[45]
Neuroblastoma	Activated and stem cell-derived NK cells; GD2-CAR iPSC-NK; PDX models	High NK sensitivity and robust tumor clearance	Missing-self recognition and GD2 tumor selectivity	[58,62]
Osteosarcoma	Primary samples; iPSC-NK; IL-15 activation	> 60% cytotoxicity in primary tumors with enhanced efficacy	HLA-independent recognition enables allogeneic strategies	[63-65]
Other pediatric solid tumors	NK receptor-ligand profiling; cytotoxicity screens	Variable but measurable NK responsiveness	Guides tumor-specific NK optimization	[55]
Mechanistic advantages	Engineered NK vs CAR-T comparative studies	Multi-receptor recognition limits antigen escape	Enhanced efficacy in heterogeneous tumors	[56]
Immunomodulatory effects	Immune coculture and in vivo remodeling models	Activation of dendritic cells and T-cell priming	Supports durable immune surveillance	[57]
Integrated translational outlook	Aggregate pediatric tumor models	Strong rationale for clinical translation	Guides biomarker-driven development strategies	[50-69]

The table provides an overview of preclinical research on stem cell-derived immune effector cells, with a focus on induced pluripotent stem cell-derived natural killer cells, which target both pediatric hematologic and solid malignancies. Data from in vitro functional assays and in vivo xenograft models demonstrate robust antitumor efficacy, favorable safety profiles, and insights into the underlying biological mechanisms. Genetic enhancements, including chimeric antigen receptor integration and cytokine pathway optimization, such as interleukin-15 expression, are highlighted for their role in increasing the cytotoxic potency, persistence, and durability of antitumor responses. Overall, these studies underscore the promising translational and clinical potential of stem cell-based immune therapies in pediatric cancer treatment. ALL: Acute lymphoblastic leukemia; iPSCs: Induced pluripotent stem cells; CAR: Chimeric antigen receptor; NK: Natural killer; GvHD: Graft-vs-host disease; IL: Interleukin; HLA: Human leukocyte antigen.

CLINICAL TRANSLATION AND EARLY TRIAL DATA

Over the past 5 years, the progression of stem cell-derived immune cell therapies from experimental models to clinical evaluation has advanced at a remarkable pace. Multiple early-phase clinical studies have established both the safety and early signs of the clinical benefit of these novel therapeutic platforms in adult and pediatric patient populations. Among these strategies, iPSC-derived NK cell therapies have undergone particularly rapid clinical maturation, with several candidates successfully entering phase I trials and demonstrating promising antitumor activity in hematologic cancers[59].

FT596 is currently the most advanced iPSC-derived CAR-NK cell therapy in clinical development. Developed by Fate Therapeutics, FT596 is designed as an off-the-shelf, allogeneic treatment for B-cell malignancies. The product incorporates multiple genetic enhancements, including a CD19-specific CAR to enable targeted tumor recognition, a high-affinity, noncleavable CD16 receptor to potentiate ADCC, and an IL-15 receptor fusion construct that supports NK cell survival, persistence, and expansion. Phase I clinical studies have assessed FT596 both as a standalone therapy and in combination with rituximab in patients with relapsed or refractory B-cell lymphomas[60].

Early clinical findings from the FT596 trial revealed a favorable safety profile accompanied by encouraging efficacy signals. In patients receiving FT596 monotherapy, no dose-limiting toxicities were reported, and treatment was generally well tolerated, with adverse events that were manageable. Notably, no instances of graft-vs-host disease were observed, underscoring the intrinsic safety advantage of NK cell-based therapies over allogeneic T-cell approaches. Initial evidence of antitumor activity included objective clinical responses, with several patients achieving partial or complete remission[61].

The therapeutic activity of FT596 was further enhanced when it was administered in combination with rituximab. This combinatorial strategy is mechanistically supported by the engineered high-affinity CD16 receptor expressed by FT596 cells, which augments ADCC in the presence of the anti-CD20 monoclonal antibody rituximab. Preliminary results from combination therapy cohorts have reported objective response rates of approximately 60% in heavily pretreated patients with relapsed or refractory B-cell lymphomas, highlighting the substantial therapeutic promise of this approach[62].

FT516 is another iPSC-derived NK cell product currently undergoing clinical evaluation. While incorporating engineering features similar to those of FT596, FT516 does not include a CD19-targeted CAR, allowing it to function as a versatile immune effector when paired with tumor-directed monoclonal antibodies. This platform is intended to enhance ADCC across a range of malignancies. Phase I trials have investigated FT516 in combination with therapeutic antibodies such as trastuzumab for HER2-positive solid tumors and rituximab for B-cell malignancies[63].

Clinical data from FT516 studies have demonstrated that this product can safely potentiate the antitumor effects of monoclonal antibody therapies without introducing substantial additional toxicity. Compared with historical controls, patients treated with FT516 alongside standard-of-care antibodies have shown improved response rates, supporting the clinical value of this strategy. Moreover, the standardized manufacturing process characteristic of iPSC-derived products has enabled consistent dosing and predictable pharmacokinetic behavior across diverse patient populations[64].

Cord blood-derived CD19-targeted CAR-NK therapies have provided important clinical validation of the NK cell platform, particularly in pediatric oncology. In a phase I study reported by Liu et al[1], 11 patients with relapsed or refractory CD19-positive lymphoid malignancies were treated with cord blood-derived CAR-NK cells engineered to express IL-15. The trial demonstrated notable clinical efficacy, with 8 of 11 patients (73%) achieving objective responses, including seven complete remissions. Importantly, treatment was not associated with cytokine release syndrome, neurotoxicity, or graft-vs-host disease, confirming the favorable safety profile of CAR-NK cell therapy.

The durability of the responses observed in this cord blood CAR-NK trial has been particularly encouraging, with several patients maintaining complete remission for more than 1 year after therapy. These sustained responses suggest that CAR-NK cells may establish effective immune surveillance capable of long-term tumor control. In addition, the absence of T-cell-related toxicity has enabled outpatient administration in many cases, reducing healthcare utilization and enhancing patient quality of life[65,66]. Across multiple CAR-NK clinical studies, the consistent lack of graft-vs-host disease has reinforced a central theoretical advantage of NK-cell-based immunotherapies. This safety feature is especially critical in pediatric patients, for whom graft-vs-host disease can result in severe and lasting complications. The reduced toxicity burden of NK cell therapies may therefore expand treatment eligibility to younger patients and those with limited functional reserves who are not suitable candidates for aggressive T-cell-based interventions[67].

Efficacy outcomes from early-phase CAR-NK trials have demonstrated meaningful clinical activity across a range of hematologic malignancies. The reported response rates in heavily pretreated patient cohorts generally range from 40% to 70%, depending on the disease subtype and patient-specific factors. These results compare favorably with available salvage therapies while offering substantially improved safety profiles. The high manufacturing consistency inherent to stem cell-derived products has further contributed to predictable therapeutic responses and minimized inter-batch variability[68].

A major advantage of stem cell-derived NK cell therapies lies in their suitability for off-the-shelf, allogeneic use, in contrast to autologous CAR-T-cell approaches. The ability to manufacture, perform quality tests, and cryopreserve therapeutic cell products in advance allows rapid treatment initiation when clinically indicated. Clinical experience has confirmed that iPSC-derived NK cells retain their full functional capacity following cryopreservation and thawing, supporting scalable global distribution and efficient inventory management[69].

Scalable manufacturing has been achieved through the production of multiple clinical grade lots exhibiting consistent quality attributes. The establishment of master cell banks from well-characterized iPSC clones enables the generation of thousands of patient doses from a single source material, providing both economic advantages and broad clinical accessibility. Extensive quality control assessments have verified the genetic integrity, phenotypic stability, and functional reproducibility of iPSC-derived NK cells across multiple manufacturing runs[70].

To further enhance therapeutic efficacy, combination strategies involving stem cell-derived NK cells are actively being explored. Clinical studies evaluating NK cell therapies in conjunction with immune checkpoint inhibitors, monoclonal antibodies, and small-molecule agents have demonstrated synergistic effects in selected patient populations. These findings suggest that NK cell-mediated immunomodulation can potentiate the activity of complementary immunotherapeutic modalities, providing a strong rationale for combination-based treatment paradigms[71].

Clinical trial designs have increasingly incorporated pediatric-specific considerations, including age-adjusted dosing regimens, intensified safety surveillance, and tailored supportive care protocols. The favorable safety profile of NK cell therapies has facilitated the inclusion of pediatric patients in early-phase trials, enabling the generation of critical safety and efficacy data in this population. Ongoing long-term follow-up studies are being conducted to evaluate potential delayed effects, particularly in the context of immune system development during childhood[72]. Table 2 provides a summary of the clinical advancements, safety profiles, and early efficacy outcomes of stem cell-derived NK cell therapies.

Table 2 Translational and early clinical evidence supporting stem cell-derived natural killer cell therapies.

Domain/emphasis	Therapeutic product or platform	Clinical development stage and context	Principal clinical observations and translational implications	Ref.
Overall field evolution	iPSC-derived NK cell platforms (collective experience)	Multiple first-in-human and phase I trials in adult and pediatric cohorts	Over the last five years, stem cell-derived NK therapies have progressed rapidly into clinical testing, with early trials demonstrating acceptable safety profiles and initial signals of antitumor activity, particularly in hematologic malignancies	[70]
Most advanced candidate -FT596	FT596 (fate therapeutics): Allogeneic, off-the-shelf iPSC-NK incorporating CD19-directed CAR, high-affinity noncleavable CD16, and IL-15 receptor fusion	Phase I trials in relapsed/refractory B-cell lymphomas; evaluated alone and in combination with rituximab	Early clinical evaluation indicates good tolerability with no dose-limiting toxicities or graft-vs-host disease; objective responses including partial and complete remissions observed. Combination with rituximab enhances antibody-dependent cytotoxicity, achieving approximately 60% response rates in heavily pretreated patients and supporting prolonged in vivo persistence	[59-61]
Broadly applicable iPSC-NK platform - FT516	FT516: IPSC-derived NK cells engineered with enhanced Fc receptor signaling but lacking tumor-specific CAR	Phase I studies combined with monoclonal antibodies (e.g., trastuzumab in HER2-positive solid tumors; rituximab in B-cell malignancies)	Demonstrates the ability to safely potentiate antibody-mediated antitumor effects via enhanced ADCC, without introducing significant additional toxicity; exhibits consistent pharmacokinetic behavior and reliable dosing across treated individuals	[62,63]
Clinical proof-of-concept -cord blood CAR-NK	Cord blood-derived CD19 CAR-NK cells expressing IL-15 (Liu et al[1])	Phase I study in relapsed/refractory CD19-positive lymphoid cancers, including pediatric patients	High clinical activity observed, with objective responses in 73% of patients and durable complete remissions exceeding one year in several cases; notably absent were cytokine release syndrome, neurotoxicity, and graft-vs-host disease, allowing outpatient administration in many instances	[64,65]
Aggregate efficacy across CAR-NK trials	Pooled early-phase CAR-NK clinical experience	Early-phase studies in heavily pretreated hematologic malignancies	Across studies, response rates generally range between approximately 40% and 70%, comparing favorably with available salvage therapies while maintaining substantially lower rates of severe immune-related toxicities	[79]
Off-the-shelf and cryopreservation benefits	Banked iPSC-derived NK cell products	Clinical, translational, and operational evaluations	iPSC-derived NK cells preserve functional activity following cryopreservation and thawing, enabling immediate treatment availability, scalable manufacturing, and efficient global distribution	[80]
Manufacturing scalability and consistency	Master iPSC cell banks with multi-lot GMP production	GMP manufacturing programs with extensive lot release testing	A single well-characterized iPSC clone can generate thousands of therapeutic doses; repeated manufacturing runs yield products with stable genetic, phenotypic, and functional characteristics, supporting predictable clinical outcomes	[83]
Combination-based therapeutic strategies	NK cell therapies combined with monoclonal antibodies, immune checkpoint inhibitors, or small-molecule agents	Early-phase combination cohorts and translational correlative analyses	Emerging evidence supports synergistic antitumor effects in selected patient populations, providing a strong rationale for combination regimens designed to enhance efficacy and overcome tumor immune resistance	[84]
Pediatric trial considerations	Pediatric-inclusive early-phase trials with adapted protocols	Trials incorporating age-adjusted dosing, intensified safety monitoring, tailored supportive care, and long-term follow-up	The favorable toxicity profile of NK-based therapies has enabled early inclusion of pediatric patients; ongoing surveillance aims to identify potential delayed effects on immune maturation and long-term health	[85]

iPSCs: Induced pluripotent stem cells; NK: Natural killer; CAR: Chimeric antigen receptor; IL: Interleukin; ADCC: Antibody-dependent cellular cytotoxicity; GMP: Good manufacturing practice.

MANUFACTURING CHALLENGES AND GMP COMPLIANCE

The effective clinical translation of stem cell-derived immune cell therapies depends on the establishment of manufacturing platforms that are robust, scalable, and fully compliant with regulatory standards while consistently delivering high-quality cellular products. Achieving GMP compliance is a pivotal step in moving these advanced therapies from bench to bedside and requires substantial investment in specialized infrastructure, process optimization, and comprehensive quality management systems[73].

The large-scale production of stem cell-derived immune cells poses challenges that are fundamentally different from conventional pharmaceutical manufacturing. As living therapeutic entities, cellular products are highly sensitive to variations in environmental and process parameters, including temperature, pH, oxygen tension, nutrient availability, and mechanical stress. To address these challenges, bioreactor-based manufacturing platforms have become central to scale-up strategies, enabling the controlled expansion and differentiation of stem cells while preserving product consistency and functional integrity[74].

Contemporary protocols for iPSC expansion have been successfully transitioned to stirred-tank bioreactor systems capable of supporting the growth of billions of cells under tightly regulated conditions. These systems integrate real-time monitoring of critical process variables with automated feeding and control strategies, thereby minimizing batch-to-batch variability. The shift from static culture methods to dynamic bioreactor platforms has resulted in substantial gains in manufacturing scale without compromising the genetic stability or differentiation capacity of iPSC master cell banks[75].

Ensuring high and reproducible differentiation efficiency remains a central challenge in the manufacture of stem cell-derived immune cell therapies, as inconsistencies in differentiation outcomes can directly affect product potency and clinical performance. Therefore, advanced process control approaches have been developed to refine differentiation protocols, incorporating real-time assessment of cell surface phenotypes, transcriptional profiles, and functional attributes to maintain product uniformity. The application of single-cell analytical technologies has further enhanced the understanding of differentiation trajectories and enabled the identification of critical control points that govern final product quality[76].

Comprehensive quality control and product characterization strategies are essential for stem cell-derived immune cell therapies and encompass evaluations of identity, purity, potency, and safety. Testing confirmed the expression of lineage-specific markers and verified the absence of residual undifferentiated pluripotent cells or unintended cell populations. Purity analyses quantify the proportion of the target immune cell subset and detect potential contaminants, whereas potency assays assess functional activity via standardized cytotoxicity measurements and cytokine secretion profiles[77].

Maintaining genomic and epigenetic stability represents a distinct challenge for stem cell-derived products, given the extended culture durations required for cell expansion and differentiation. As a result, comprehensive genomic surveillance - including whole-genome sequencing, copy number variation analysis, and targeted mutation screening - has become the standard practice for qualifying master cell banks and monitoring stability throughout manufacturing. Complementary epigenetic assessments, such as DNA methylation profiling and chromatin accessibility analyses, provide additional insight into cellular identity, stability, and differentiation status[78].

The application of advanced analytical tools has demonstrated that iPSC-derived immune cells can retain genomic integrity during prolonged manufacturing processes when appropriate culture conditions and passage thresholds are maintained. Nevertheless, certain genomic loci have been identified as potentially vulnerable to instability during extended culture, reinforcing the need for continuous monitoring and the establishment of stringent release criteria to ensure product safety and consistency[79].

Cryopreservation strategies have been developed to preserve both the viability and functional competence of stem cell-derived immune cell products. Improvements in cryoprotectant formulations and controlled-rate freezing methodologies have enabled post-thaw viability rates to exceed 85% for iPSC-derived NK cells. Long-term storage studies have further shown that appropriately cryopreserved products can retain functional activity for more than 2 years when maintained under validated storage conditions[80,81].

The distribution of off-the-shelf cellular therapies introduces complex supply chain requirements, including ultralow-temperature storage, specialized transportation logistics, and advanced inventory management systems. Centralized manufacturing models with global distribution capabilities have been developed to support the cost-effective production and delivery of stem cell-derived immune cell therapies to clinical sites worldwide[82].

Regulatory oversight for stem cell-derived immune cell therapies continues to evolve as agencies accumulate experience with these novel products. Both the United States Food and Drug Administration and the European Medicines Agency have issued guidance documents outlining regulatory pathways for cellular therapies, with specific considerations for products derived from pluripotent stem cells. These frameworks emphasize rigorous product characterization, well-controlled manufacturing processes, and extensive safety evaluations as prerequisites for clinical development[83].

Economic considerations play a critical role in determining the commercial feasibility of stem cell-derived immune cell therapies. Although the initial investment required to establish GMP-compliant manufacturing infrastructure is considerable, the inherent scalability of stem cell-based platforms offers the potential to reduce per-patient treatment costs relative to autologous cell therapies. Economic modeling analyses suggest that iPSC-derived immune cell products may ultimately achieve cost competitiveness with existing therapeutic options while delivering superior safety and efficacy profiles[84].

To further improve manufacturing efficiency and reduce operational costs, increasing emphasis is being placed on automation and digital integration. Automated cell culture systems, robotic liquid-handling technologies, and centralized data management platforms have demonstrated the ability to increase reproducibility while decreasing reliance on manual labor. Moreover, the incorporation of artificial intelligence and machine learning tools for process optimization, quality forecasting, and real-time decision support represents a rapidly emerging frontier in cell therapy manufacturing[84].

SAFETY, ETHICAL, AND REGULATION CONSIDERATIONS

The advance of stem cell-derived immune cell therapies for pediatric oncology demands increased attention to safety, ethical, and regulatory considerations, which are inherently more complex when treating children with aggressive, life-threatening cancers. The heightened vulnerability of pediatric patients, together with the experimental nature of these therapies, necessitates intensified safety oversight, refined ethical governance, and customized regulatory strategies that carefully balance the urgent need for effective interventions with the obligation to safeguard young patients[85,86].

Unlike adult patients, pediatric patients require extended posttreatment surveillance owing to their longer life expectancy and the potential for delayed adverse effects that may manifest as developing organ systems mature. Current guidelines recommend long-term follow-up of at least 15 years for gene-modified cellular therapies administered during childhood, with some authorities supporting lifelong monitoring in selected cases. While essential for patient safety, these prolonged surveillance requirements introduce substantial logistical, financial, and psychosocial challenges for clinical trial sponsors, health care systems, and families[87,88].

Monitoring immune system recovery and development is a critical component of safety assessment in pediatric cellular immunotherapy. Because the pediatric immune system is still maturing, its response to infused immune effector cells may differ from that observed in adults, potentially influencing both therapeutic benefit and immune-related toxicity. Accordingly, comprehensive immune monitoring frameworks have been implemented to evaluate longitudinal changes in immune cell subsets, cytokine dynamics, and overall immune function following treatment[89]. Data generated to date suggest that stem cell-derived NK cell therapies do not adversely disrupt normal immune development in pediatric recipients.

The consistent absence of graft-vs-host disease in clinical trials of NK cell therapies has addressed one of the most serious safety concerns traditionally associated with allogeneic cellular treatments. Nonetheless, vigilant monitoring remains necessary for other potential immune-mediated complications, including cytokine release syndrome, tumor lysis syndrome, and on-target off-tumor effects. The comparatively favorable safety profile of NK cell-based therapies relative to T-cell-based approaches has facilitated the enrollment of younger patients and those with limited performance status in early-phase clinical studies[90].

Ethical considerations specific to pediatric populations include the complex processes of assent and informed consent in the setting of investigational therapies for severe illnesses. The emotional burden experienced by families confronting a pediatric cancer diagnosis can complicate risk-benefit assessment and decision-making. As a result, enhanced consent procedures have been developed to ensure clear communication, adequate comprehension, and appropriate psychosocial support. Institutional review boards and ethics committees overseeing pediatric trials of stem cell-derived immune cell therapies increasingly incorporate pediatric ethics specialists and community representatives to strengthen ethical oversight[91].

The experimental status of stem cell-derived immune cell therapies raises important questions regarding clinical equipoise and the justification for enrolling children in early-phase trials. While the favorable safety outcomes reported in initial studies have supported pediatric inclusion in phase I investigations, continuous ethical evaluation is needed to ensure that anticipated benefits remain proportionate to potential risks as clinical evidence evolves[92].

Regulatory frameworks governing pediatric cellular therapy development have been adapted to address both pediatric drug development mandates and the distinct attributes of living cell products. In the United States, the Pediatric Research Equity Act requires the consideration of pediatric studies for most novel therapeutics while allowing flexibility in trial timing and design based on disease severity, unmet clinical needs, and product-specific characteristics[93].

In Europe, the classification of stem cell-derived immune cell therapies as advanced therapeutic medicinal products has established regulatory pathways that acknowledge their biological complexity while maintaining rigorous safety standards. The European Medicines Agency has created specialized expert committees for the evaluation of cellular therapies and has issued guidance documents specifically addressing the development and clinical use of such products in pediatric populations[94].

Manufacturing requirements for pediatric cellular therapies often necessitate additional refinements to ensure safe and accurate dosing for smaller patients. Pediatric-specific dosing strategies, adapted manufacturing workflows, and tailored quality control measures have been introduced to meet these needs. Collectively, these modifications have been effective in preserving product consistency while enabling precise dose adjustments appropriate for pediatric patients[95].

Efforts toward international regulatory harmonization have aimed to streamline pediatric cellular therapy development across jurisdictions. The International Council for Harmonization has issued guidelines that address pediatric drug development, including considerations relevant to innovative modalities such as cell-based therapies. These harmonization initiatives have reduced regulatory fragmentation and supported more efficient global clinical development programs[96].

Finally, collaborative data-sharing initiatives and international registries have been established to capture long-term safety and efficacy outcomes across multiple institutions and clinical trials. Such efforts are particularly critical in pediatric cellular therapy research, where limited patient numbers constrain the detection of rare or delayed adverse effects within individual studies. Emerging international registries tracking patients treated with stem cell-derived immune cell therapies are beginning to generate valuable insights into long-term clinical outcomes and safety profiles[97].

FUTURE PERSPECTIVE

The development of stem cell-derived immune effector therapies for pediatric cancer has reached a critical transitional stage. Initial clinical experiences have substantiated the underlying therapeutic concept while simultaneously revealing distinct technical, biological, and translational barriers that must be resolved before these approaches can be broadly implemented in routine clinical practice. Continued integration of advances in pluripotent and HSC biology with high-precision genome engineering, together with a more refined understanding of pediatric tumor immunobiology, will be central to the generation of next-generation cellular immunotherapies with enhanced safety, functional durability, and tumor-selective activity[98].

Comparative and standardized preclinical assessment

A systematic delineation of the advantages and limitations of iPSC- and HSC-derived NK cells, T cells, and DCs requires rigorous harmonized, head-to-head preclinical investigations[99]. Such studies should rely on shared orthotopic and patient-derived xenograft models, unified potency readouts - including multiantigen cytotoxicity, ADCC, and cytokine secretion profiles - and standardized correlative platforms encompassing single-cell transcriptomic and epigenomic analyses, metabolic characterization, and longitudinal in vivo imaging. Reproducible quantitative parameters, such as in vitro EC50 and killing kinetics, in vivo tumor growth suppression, cellular persistence half-life, and the frequency of antigen-loss variants under immune pressure, are essential for defining disease-specific clinical applications and establishing predictive biomarkers to inform early-phase clinical decision-making.

Mechanistic analysis and control of manufacturing instability

Elucidation of the molecular mechanisms driving genomic and epigenomic instability, differentiation variability, and progressive functional decline during large-scale expansion is a critical priority. Longitudinal multiomics profiling, including whole-genome sequencing, copy number analysis, DNA methylation mapping, transcriptomics, telomere dynamics, and indicators of replication stress, should be systematically applied across discrete manufacturing stages, from master cell banks to final drug products. These analyses should be integrated with controlled perturbation experiments evaluating oxygen tension, nutrient availability, and small-molecule epigenetic regulators within bioreactor-based culture systems. Mitigation strategies, such as the use of early-passage master banks, optimized culture conditions, and routine genomic and epigenomic quality control, must be validated by demonstrable reductions in de novo alterations and improved batch-to-batch consistency in functional potency.

Establishment of predictive potency and safety testing frameworks

There is a pressing need to define a streamlined but robust set of regulatory-compliant assays capable of predicting clinical performance. Essential assay components should include panels assessing multiantigen cytotoxic activity, ADCC functionality, cytokine release profiles, sensitive detection of residual undifferentiated cells, and complementary methodologies for identifying off-target genome-editing events. Each assay should undergo formal validation for sensitivity, specificity, and inter-laboratory reproducibility, with prospective correlation to outcomes in sentinel in vivo models to support clinically actionable product release criteria.

Engineering strategies to balance immune evasion, efficacy, and controllability

Future engineering efforts should focus on optimizing immune evasion and antitumor efficacy while maintaining stringent safety control. Key priorities include rational modulation of HLA expression or implementation of immune-cloaking strategies to reduce host-mediated clearance, deployment of multiantigen or tandem receptor configurations to mitigate antigen escape, metabolic reprogramming to increase tumor infiltration and survival within immunosuppressive microenvironments, and incorporation of rapid, reliable inducible safety switches such as iC9 or small-molecule-regulated systems. All engineering modifications should be evaluated in pediatric-relevant in vivo models to define trade-offs among persistence, cytotoxic potency, and external controllability[100].

Rational combination strategies and pediatric-focused clinical trial design

Early-phase clinical studies should be specifically structured to interrogate sequencing and dosing variables for combination regimens involving lymphodepletion, immune checkpoint inhibitors, monoclonal antibodies, radiotherapy, and targeted agents. Hypothesis-driven clinical frameworks may include: (1) Lymphodepletion followed by cell infusion with delayed checkpoint blockade administered 7-14 days later to promote engraftment while limiting premature exhaustion; (2) Concurrent administration of stem cell-derived immune cells with ADCC-enabled monoclonal antibodies delivered at infusion and at weekly intervals to exploit engineered CD16 variants; and (3) Low-dose, tumor-priming radiotherapy delivered 24-72 hours prior to cell infusion to increase antigen release and DC activation. Conservative dose-escalation designs incorporating repeat-dosing cohorts and predefined biomarker-guided stopping or expansion rules will be essential to maximize both safety and interpretability. Early integration of correlative biomarkers, such as immune repertoire dynamics, tumor antigen landscapes, and cellular persistence, will further support adaptive trial optimization in pediatric populations[101].

Economic, regulatory, and long-term safety considerations

Transparent analyses of manufacturing costs and health-economic outcomes are needed to compare centralized iPSC-based platforms, cord blood or HSC-derived products, and autologous CAR-T-cell therapies, incorporating sensitivity analyses related to production scales and manufacturing models. Early and sustained engagement with regulatory authorities and payers will be critical to harmonize pediatric-specific endpoints, acceptable surrogate markers, and expectations for long-term follow-up. In parallel, interoperable international registries with a minimum follow-up duration of 15 years should be established for gene-modified products to enable the detection of rare or delayed adverse events and to support pooled assessments of long-term safety and effectiveness.

Collaborative frameworks and equitable access

The establishment of multi-institutional consortia will be instrumental in accelerating progress through shared access to reference master cell banks, standardized assay protocols, and deidentified correlative data sets, thereby increasing reproducibility and cross-validation. In addition, the development of regional manufacturing hubs and structured technology-transfer initiatives may substantially reduce per-patient costs and expand geographic accessibility, provided that centralized quality-control standards and regulatory compliance are rigorously maintained. Collectively, the coordinated implementation of this research and translational agenda - grounded in mechanistic understanding, assay standardization, pediatric-specific clinical strategies, and transparent economic planning - will be essential to transform encouraging preclinical and early clinical findings into durable, scalable, and widely accessible immunotherapeutic solutions for children with cancer.

CONCLUSION

Stem cell-derived immune cell therapies integrate strong biological rationales with unparalleled engineering versatility and scalable production capacity, positioning them as promising off-the-shelf immunotherapeutic options for select pediatric cancers. Emerging evidence, particularly from engineered iPSC-derived NK cell platforms and cord blood-based CAR-NK approaches, supports favorable safety profiles and early signs of antitumor activity. However, widespread clinical implementation will require robust comparative efficacy studies, stringent control of manufacturing fidelity at the genomic and differentiation levels, transparent demonstrations of cost-effectiveness, and pediatric-specific clinical trial designs incorporating extended follow-up. Progress in these areas, driven by coordinated preclinical standardization, mechanistic insight, and carefully optimized combination strategies, will be essential to translate the current experimental momentum into durable and equitable clinical benefit for children with cancer.